GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiNK Therapeutics Inc (NAS:INKT) » Definitions » 6-1 Month Momentum %

MiNK Therapeutics (MiNK Therapeutics) 6-1 Month Momentum % : -17.05% (As of May. 24, 2024)


View and export this data going back to 2021. Start your Free Trial

What is MiNK Therapeutics 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-05-24), MiNK Therapeutics's 6-1 Month Momentum % is -17.05%.

The industry rank for MiNK Therapeutics's 6-1 Month Momentum % or its related term are showing as below:

INKT's 6-1 Month Momentum % is ranked worse than
62.23% of 1525 companies
in the Biotechnology industry
Industry Median: -4.76 vs INKT: -17.05

Competitive Comparison of MiNK Therapeutics's 6-1 Month Momentum %

For the Biotechnology subindustry, MiNK Therapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MiNK Therapeutics's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MiNK Therapeutics's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where MiNK Therapeutics's 6-1 Month Momentum % falls into.



MiNK Therapeutics  (NAS:INKT) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MiNK Therapeutics  (NAS:INKT) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


MiNK Therapeutics 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of MiNK Therapeutics's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


MiNK Therapeutics (MiNK Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T cell therapies to treat cancer and other life-threatening illnesses.
Executives
Agenus Inc 10 percent owner 3 FORBES ROAD, LEXINGTON MA 02421
Garo H Armen director 3 FORBES ROAD, LEXINGTON MA 02421
Ulf Wiinberg director
Brian Corvese director C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Christine M Klaskin officer: Treasurer 3 FORBES ROAD, LEXINGTON MA 02421
Jennifer Buell director, officer: See Remarks 3 FORBES ROAD, LEXINGTON MA 02421
Barbara Ryan director 22 CAVRAY ROAD, NORWALK CT 06855
Walter Md Flamenbaum director 3 FORBES ROAD, LEXINGTON MA 02421
John Baldoni director 3 FORBES ROAD, LEXINGTON MA 02421
Peter Behner director 3 FORBES ROAD, LEXINGTON MA 02421
Van Dijk Marcus Antonius officer: Chief Technology Officer 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010